Kura Oncology, Inc. (KURA) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
KURA Revenue Growth
Revenue Breakdown (FY 2025)
KURA's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
KURA Revenue Analysis (2014–2025)
As of May 8, 2026, Kura Oncology, Inc. (KURA) generated trailing twelve-month (TTM) revenue of $67.5 million, reflecting significant decline in growth of -67.8% year-over-year. The most recent quarter (Q4 2025) recorded $17.3 million in revenue, down 16.5% sequentially.
Looking at the longer-term picture, KURA's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $67.5 million in 2025, representing a new all-time high.
Revenue diversification analysis shows KURA's business is primarily driven by Collaboration Revenue (97%), and Product (3%). With over half of revenue concentrated in Collaboration Revenue, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including MGNX (+0.8% YoY), TPVG, and AGIO (+78.3% YoY), KURA has underperformed the peer group in terms of revenue growth. Compare KURA vs MGNX →
KURA Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| KURACurrent | $67M | -67.8% | - | -449.9% | |
 MGNX | $150M | +0.8% | +8.9% | -48.7% | |
 TPVG | $97M | - | - | 77.9% | |
 AGIO | $54M | +78.3% | - | -873.9% |
KURA Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $67.5M | +25.2% | $67.4M | 99.9% | $-303,631,000 | -449.9% |
| 2024 | $53.9M | - | $53.9M | 100.0% | $-193,195,000 | -358.5% |
| 2023 | $0 | - | $-849,000 | - | $-165,804,000 | - |
| 2022 | $0 | - | $0 | - | $-139,865,000 | - |
| 2021 | $0 | - | $0 | - | $-131,258,000 | - |
| 2020 | $0 | - | $-194,000 | - | $-91,899,000 | - |
| 2019 | $0 | - | $0 | - | $-67,479,000 | - |
| 2018 | $0 | - | $-10,000 | - | $-62,883,000 | - |
| 2017 | $0 | - | $-30,000 | - | $-36,077,000 | - |
| 2016 | $0 | - | $-31,000 | - | $-28,367,000 | - |
See KURA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs KURA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare KURA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonKURA — Frequently Asked Questions
Quick answers to the most common questions about buying KURA stock.
Is KURA's revenue growth accelerating or slowing?
KURA revenue declined -67.8% year-over-year, contrasting with the 5-year CAGR of N/A. TTM revenue fell to $67M. This reverses the prior growth trend.
What is KURA's long-term revenue growth rate?
Kura Oncology, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of -67.8% is below this long-term average.
How is KURA's revenue distributed by segment?
KURA reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.